8FIU

Potent long-acting inhibitors targeting HIV-1 capsid based on a versatile quinazolin-4-one scaffold

8FIU の概要

• エントリーDOI: 10.2210/pdb8fiu/pdb
• 分子名称: HIV-1 capsid, 1,2-ETHANEDIOL, N-[(1S)-1-{(3P)-3-{4-chloro-3-[(methanesulfonyl)amino]-1-methyl-1H-indazol-7-yl}-7-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-4-oxo-3,4-dihydroquinazolin-2-yl}-2-(3,5-difluorophenyl)ethyl]-2-[(3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl]acetamide, ... (4 entities in total)
• 機能のキーワード: hiv-1, capsid, ligand complex, antiviral protein, antiviral-protein-inhibitor complex, antiviral-protein/inhibitor
• 由来する生物種: Human immunodeficiency virus 1
• タンパク質・核酸の鎖数: 3
• 化学式量合計: 79966.80

構造登録者

Nolte, R.T. (登録日: 2022-12-16, 公開日: 2023-02-15, 最終更新日: 2024-10-23)

主引用文献

Gillis, E.P.,Parcella, K.,Bowsher, M.,Cook, J.H.,Iwuagwu, C.,Naidu, B.N.,Patel, M.,Peese, K.,Huang, H.,Valera, L.,Wang, C.,Kieltyka, K.,Parker, D.D.,Simmermacher, J.,Arnoult, E.,Nolte, R.T.,Wang, L.,Bender, J.A.,Frennesson, D.B.,Saulnier, M.,Wang, A.X.,Meanwell, N.A.,Belema, M.,Hanumegowda, U.,Jenkins, S.,Krystal, M.,Kadow, J.F.,Cockett, M.,Fridell, R.
Potent Long-Acting Inhibitors Targeting the HIV-1 Capsid Based on a Versatile Quinazolin-4-one Scaffold.
J.Med.Chem., 66:1941-1954, 2023

PubMed Abstract: Long-acting (LA) human immunodeficiency virus-1 (HIV-1) antiretroviral therapy characterized by a ≥1 month dosing interval offers significant advantages over daily oral therapy. However, the criteria for compounds that enter clinical development are high. Exceptional potency and low plasma clearance are required to meet dose size requirements; excellent chemical stability and/or crystalline form stability is required to meet formulation requirements, and new antivirals in HIV-1 therapy need to be largely free of side effects and drug-drug interactions. In view of these challenges, the discovery that capsid inhibitors comprising a quinazolinone core tolerate a wide range of structural modifications while maintaining picomolar potency against HIV-1 infection , are assembled efficiently in a multi-component reaction, and can be isolated in a stereochemically pure form is reported herein. The detailed characterization of a prototypical compound, GSK878, is presented, including an X-ray co-crystal structure and subcutaneous and intramuscular pharmacokinetic data in rats and dogs.

PubMed: 36719971
DOI: 10.1021/acs.jmedchem.2c01732

実験手法

X-RAY DIFFRACTION (1.56 Å)